• ATN Ac PHSCN NH is a small peptide antagonist

  2022-01-03

  

  ATN-161 (Ac-PHSCN-NH2) is a small peptide antagonist of integrin α5β1, a recently developed anticancer drug that interacts with the N-terminus of the β1 region of integrin α5β1 to lock integrin α5β1 in its non-activated conformation (Wang et al., 2016). The drug has been tested in Phase 2 clinical t

• In our cohort each patient

  2022-01-03

  

  In our cohort, each patient had a median of 2 Anti-FXa measurements performed daily and a median of 1 infusion rate change daily to maintain therapeutic unfractionated heparin levels. Previously, several studies have documented that APTT-based protocols lead to more fluctuations in comparison with A

• In summary tail vein injection of

  2022-01-03

  

  In summary, tail vein injection of mmLDL activated the ERK1/2 signaling pathway, leading to increased serum concentrations and increased vascular wall expression of ICAM-1 and VCAM-1, and may cause increased expression of vascular smooth muscle ETB receptors and the ETB receptor-mediated contractile

• Thus both in Drosophila and mammals the

  2022-01-03

  

  Thus, both in Drosophila and mammals, the Hippo pathway responds to cell–cell junctions via an apical NF2/Mer-containing complex. Indeed, Hippo signalling and NF2 are required for contact inhibition of growth in cell culture, which is thought to reflect an in vivo function as a sensor of tissue crow

8494 records 567/567 page Previous First page 上5页 566567